Analysts Set Novartis AG (VTX:NOVN) Target Price at CHF 95.75

Shares of Novartis AG (VTX:NOVN) have been assigned an average rating of “Hold” from the twelve brokerages that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is CHF 96.25.

NOVN has been the topic of several recent analyst reports. Barclays set a CHF 85 target price on shares of Novartis and gave the stock a “sell” rating in a research note on Tuesday. Liberum Capital set a CHF 100 target price on shares of Novartis and gave the stock a “buy” rating in a research note on Wednesday, January 22nd. Goldman Sachs Group set a CHF 113 target price on shares of Novartis and gave the stock a “buy” rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. set a CHF 91 target price on shares of Novartis and gave the stock a “sell” rating in a research note on Monday, January 27th. Finally, Kepler Capital Markets set a CHF 91 target price on shares of Novartis and gave the stock a “neutral” rating in a research note on Wednesday, January 29th.

Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

See Also: Why do commodities matter?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.